Journal of Critical Care publishes positive results from prespecified, biomarker-guided subgroup analysis of AdrenoMed’s Phase II AdrenOSS-2 trial in septic shock
Precision medicine approach: Targeted treatment using two biomarkers (bio-ADM and DPP3) identifies septic shock patients most likely to benefit from enibarcimab treatment Promising clinical results: Peer-reviewed data show enibarcimab improves organ function and reduces 28-day
20. May 2025
